- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 2,482
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer
- Interventions
- SIM0505 for injection
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 6 more
- Conditions
- Cancer
- Interventions
- fatigue assessment and management, management of therapy complications, psychosocial assessment and care
- Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 9
- States / cities
- Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more
- Conditions
- Ovarian Cancer
- Interventions
- Technology-based Mindful Living program, Technology-based Healthy Lifestyles program
- Behavioral
- Lead sponsor
- Susan Lutgendorf
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 341 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • Iowa City, Iowa • Omaha, Nebraska + 1 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- hCG
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 37 Years · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Recurrent or Metastatic Solid Tumors
- Interventions
- Ifinatamab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis, Ovarian Cancer
- Interventions
- calcium, cholecalciferol, zoledronic acid
- Dietary Supplement · Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Madison, Wisconsin
- Conditions
- Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma, Advanced Recurrent Serous Ovarian Cancer, Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)
- Interventions
- BAY2287411
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Houston, Texas
- Conditions
- High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Mirvetuximab soravtansine, Carboplatin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Fresno, California • Fullerton, California + 30 more
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
- Interventions
- DT2216, Paclitaxel
- Drug
- Lead sponsor
- Elizabeth Stover, MD, PhD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Stage III Ovarian Cancer
- Interventions
- Decision Aid
- Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Breast Neoplasm, Hereditary Neoplastic Syndrome, Melanoma, Ovarian Neoplasm
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
- Conditions
- Turner Syndrome, Hypogonadism, Premature Ovarian Failure
- Interventions
- 17 beta estradiol
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 10 Years to 16 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Cvac, Placebo
- Biological
- Lead sponsor
- Prima BioMed Ltd
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
- Conditions
- Recurrent Platinum Resistant Ovarian Cancer
- Interventions
- cediranib and olaparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Downey, California + 21 more
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Paclitaxel, Pazopanib Hydrochloride, Placebo
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 142
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Burbank, California + 106 more
- Conditions
- Solid Tumors
- Interventions
- RMC-5552
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Irvine, California • Sacramento, California • San Francisco, California + 5 more
- Conditions
- Ovarian Cancer
- Interventions
- Paclitaxel, Lovastatin
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
- Interventions
- Carboplatin, Mirvetuximab Soravtansine, Bevacizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 64 more
- Conditions
- Ovarian Cancer
- Interventions
- Glufosfamide
- Drug
- Lead sponsor
- Eleison Pharmaceuticals LLC.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Greenbrae, California + 7 more
- Conditions
- Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Interventions
- PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 17
- States / cities
- Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more
- Conditions
- Ovarian Cancer
- Interventions
- EC-17
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Ovarian Neoplasms
- Interventions
- Telcyta, Liposomal Doxorubicin
- Drug
- Lead sponsor
- Telik
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 63
- States / cities
- Casa Grande, Arizona • Little Rock, Arkansas • Antioch, California + 49 more
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer
- Interventions
- NC410
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Bethesda, Maryland • Hackensack, New Jersey • New York, New York + 2 more